Skip to main content

Oyster Point Pharma, Inc.

OYSTDelisted Jan 3, 2023
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001720725

Oyster Point Pharma, Inc. was delisted on Jan 3, 2023; its insiders filed their last Form 4 on Jan 5, 2023; 53 institutions reported holding it in 13F filings for Q4 2022, worth $189.4M in total; no superinvestor held it.

Currency
USD
Source
SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
Updated
Oct 8, 2026, 2:04 PM ET

Revenue flow, FY2021

Where the revenue went in FY2021, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.

Net loss for FY2021: $100.7M (410.2% of revenue).

Income statement

Each column is one fiscal year, newest first.

Income statement of Oyster Point Pharma, Inc., annual
Line itemFY2021FY2020FY2019
Period endDec 31, 2021Dec 31, 2020Dec 31, 2019
Filing10-K10-K10-K
ReportedFeb 24, 2022Feb 18, 2021Feb 27, 2020
Revenue$24.5M––
Cost of revenue$1.52M––
Operating expenses$119.7M$71.0M$47.3M
Research and development$24.2M$39.8M$33.6M
Selling, general and administrative$40.8M$31.2M$13.7M
Operating income-$96.7M-$71.0M-$47.3M
Interest expense$3.73M––
Income tax$0$0$0
Net income-$100.7M-$70.5M-$45.7M
EPS, basic$-3.87––
EPS, diluted$-3.87––
Weighted shares, basic26.0M––
Weighted shares, diluted26.0M––
Margins and growth
Operating margin-393.9%––
Net margin-410.2%––

Balance sheet

Each column is one fiscal year, newest first.

Balance sheet of Oyster Point Pharma, Inc., annual
Line itemFY2021FY2020FY2019
Period endDec 31, 2021Dec 31, 2020Dec 31, 2019
Filing10-K10-K10-K
ReportedFeb 24, 2022Feb 18, 2021Feb 27, 2020
Cash and equivalents$193.4M$192.6M$139.1M
Accounts receivable$6.66M––
Inventory$6.09M––
Total current assets$215.3M$196.4M$142.2M
Property, plant and equipment$2.50M$804.0K$181.0K
Total assets$222.6M$197.9M$143.2M
Accounts payable$6.50M$2.28M$500.0K
Total current liabilities$28.8M$11.0M$5.40M
Long-term debt$89.8M––
Total liabilities$123.1M$11.3M$5.91M
Shareholders' equity$99.5M$186.7M$137.3M

Cash flow statement

Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.

Cash flow statement of Oyster Point Pharma, Inc., annual
Line itemFY2021FY2020FY2019
Period endDec 31, 2021Dec 31, 2020Dec 31, 2019
Filing10-K10-K10-K
ReportedFeb 24, 2022Feb 18, 2021Feb 27, 2020
Operating cash flow-$89.4M-$58.4M-$40.8M
Capital expenditures$1.49M$700.0K$200.0K
Free cash flow-$90.9M-$59.1M-$41.0M
Depreciation and amortization$141.0K$77.0K$19.0K
Stock-based compensation$11.9M$6.97M$3.27M
Investing cash flow-$1.49M-$700.0K-$200.0K
Financing cash flow$91.6M$112.5M$175.0M
Net change in cash$787.0K$53.4M$134.0M
Ratio
Stock-based compensation, % of revenue48.7%––

Shares outstanding

Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.

Shares outstanding for Oyster Point Pharma, Inc. by cover date
Cover dateShares outstandingChange in a yearFiling
Nov 4, 202226.8M+2.6%SEC
Aug 5, 202226.8M+3.1%SEC
Apr 29, 202226.7M+2.7%SEC
Feb 16, 202226.6M+2.8%SEC
Oct 29, 202126.2M+1.1%SEC
Jul 30, 202126.0M+1.0%SEC
Apr 30, 202126.0M+21.5%SEC
Feb 1, 202125.9M+21.3%SEC

Notes and known gaps

How these numbers are put together, and what they can't tell you.

  • Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
  • Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.

Known gaps

  • Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
  • EPS and share counts are as reported at the time, not adjusted for later stock splits.
  • For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
  • For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
  • Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
  • Depreciation and amortization is missing for some companies that report it under their own XBRL tags.